Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DNX-2401||Ad5-Delta24RGD|DNX2401||DNX-2401 is an adenovirus that replicates in Rb1/p16-deficient cells, resulting in lysis of tumor cells (PMID: 29432077).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||malignant glioma||not applicable||DNX-2401||Phase I||Actionable||In a Phase I trial, DNX-2401 treatment demonstrated virus-induced oncolysis in patients' tumors, resulted in more than 95% tumor reduction in 3 patients, and survival for more than 3 years in 20% (5/25) of patients with recurrent malignant glioma (PMID: 29432077; NCT02197169).||29432077|
|Unknown unknown||malignant glioma||not applicable||DNX-2401||Phase I||Actionable||In a Phase I trial, DNX-2401 treatment resulted in tumor reduction in 72% (18/25), complete response in 12% (3/25) and prolonged stable disease in 8% (2/25) of patients with recurrent malignant glioma, with a median overall survival of 9.5 months and progression-free survival of more than 3 years in patients achieved complete responses (PMID: 29432077).||29432077|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03896568||Phase I||DNX-2401||Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma||Recruiting|
|NCT02197169||Phase I||DNX-2401 DNX-2401 + Interferon gamma||DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I)||Completed|